NM Medical Psilocybin Program

Throughout 2026, I have attended meetings of the Medical Psilocybin Advisory Board and contributed to developing regulations through all seven of its working committees. The process was very active in the early months. Now it is winding down as rules are approved and the program prepares to launch.

Overall the process has been remarkably well informed and respectful, as the Department of Health and the many people who stepped up as volunteers crafted a working program within the parameters of the legislation. There have been a few rough spots, and we're not done yet. But despite inheriting the absurdity of the drug war, New Mexicans have acted with intelligence and goodwill to make the most of the opportunity we were given. I don't recall a single mention of political parties all year, except to note how legislators across the spectrum came together to pass the Act.

The New Mexico Medical Psilocybin Act was passed in April, 2025 with strong bi-partisan support. It passed 33-4 in the state Senate and 56-8 in the state House of Representatives. No public vote was required.

This Act is limited to qualifying medical conditions, unlike Oregon where any adult can access services without a diagnosis, and Colorado which has provision for personal use. However, it provides support to make services available to people who need help and could not afford other options, and will allow us to develop a foundation for whatever possibilities may evolve in the future. The open regulatory development process has catalyzed the New Mexico psychedelic therapy community into constructive collective action. Other states, including those that are not ready to consider legal personal use, are studying this model.

What it is: A statewide regulatory system that allows for the use of whole psilocybin mushrooms within a program that involves preparation, support during dosing, and follow up integration.

What it is not: Decriminalization or general legalization. No provisions for growing, gifting, or use outside of the regulated system. No dispensaries.
Mushrooms remain federally illegal, even when prescription psilocybin is rescheduled.

Whole mushrooms only. Does not affect any other natural medicines or substances.

Patient qualifications: The initial qualifying conditions are PTSD, Treatment Resistant Depression, Substance Use Disorder (any substances), and End of Life Care. Approval for additional conditions will be requested in future state legislative sessions.

Definition of "end of life care", the one condition that is not a diagnostic category, is being determined. We hope this will cover a range of potentially life-threatening conditions that bring up issues around mortality. It may include loved ones and caregivers.

Service delivery will be allowed in a variety of approved settings. Sessions at home and in nature are possible if safety conditions are satisfied.

Training: As of November, 2026, requirements for those who accompany medicine sessions are still being finalized. The proposed regulations have completed public comment and the Department of Health is preparing the final rules. Overall they resemble Colorado's with somewhat fewer didactic hours and more practicum. Until approved New Mexico training programs are running and people have had time to complete them, a reciprocity period will apply. In the first phase, the state will issue permits to New Mexico residents who have met Oregon and Colorado licensing requirements.

"Practitioners" are licensed medical and mental health professionals who complete the additional psychedelic training.
"Facilitators" do not need those professional licenses but must meet similar psychedelic facilitator training requirements.
Regulations and best practice guidelines for how teams can work together are in development.

Permits will be given rather than licenses. Unlike other states, there will be no permitting fees for producers, practitioners, facilitators, or service sites.

There are no prescriptions in this system. Decisions about dosage will be made by the team that provides services.

There will be no dispensaries. This system is very different than medical cannabis.

Funding: $630,000 was authorized for payments to cover services for low income patients. In addition, efforts are underway to align this program with Medicaid, Medicare, and insurance to allow for as much support as possible, outside of the mushrooms and medicine session costs. The University of New Mexico was awarded $300,000 to research end of life anxiety with mushrooms. More funding will be sought in future legislative years.

An Advisory Board was selected in 2025 and has been meeting throughout the past year. One of their first acts was to set up seven committees to work on various parts of the program. Committees include: Patient Qualification and Safety; Equity, Access, and Cultural Considerations; End of Life Care; Research and Continuous Improvement; Propagation; Dosage, Administration, and Clinical Practice; and Training and Education.

The Process: The committees have been meeting throughout 2026 to develop recommendations for Board approval. The Board then considers these, approves them with or without modification, and passes them along to the Department of Health. The DoH then posts their proposed regulations for public comment online and holds a live public comment meeting. After considering the response, they adopt and publish the rules.

Additional qualifying conditions are being considered. Legislators are interested in expanding, as long as there is sound evidence for the benefits. On the current list: Depression other than Treatment Resistant. Anxiety. Pain (potentially including cluster headaches and migraines). Neurological conditions including Parkinson's, Traumatic Brain Injury.

What about microdosing? This question has been raised frequently. At this time, it's hard to see how microdosing could fit within the requirements for preparation, supervision after dosing, and integration after each session. People are logically asking: If macrodosing is allowed, why not microdoses? The answer is that more research to support microdosing is needed.

Indigenous representation, reciprocity, and services to tribes

In addition to being half Hispanic, New Mexico has 24 federally recognized tribes: 19 Pueblos, the Navajo Nation, and three Apache tribes: the Jicarilla Apache Nation, the Mescalero Apache Tribe, and the Fort Sill Apache Tribe.

Good intentions for inclusion and access were stated in the program from the beginning. However, what actually happens with Native American communities remains to be seen, and depends on what these communities want for themselves. Plans are in the works for a listening tour and educational outreach to tribal communities, coordinated by Marlena Robbins. Psilocybin mushroom research including indigenous group sessions is in process.

In the original Medical Psilocybin Act:
Section 7(C) states that "The Department of Health must engage in tribal consultation under the State-Tribal Collaboration Act while developing the program."
Section 8(A), Advisory Board. At least one of the nine board members must be an enrolled member of an Indian nation, tribe, or pueblo located wholly or partially in New Mexico. Navajo Nation tribal member DezBaa' is on the Board and leads the Equity, Access, and Cultural Considerations committee.
Section 9, Assessment reporting. The department’s annual assessment must consider the needs of qualified patients living in rural areas, federally subsidized housing, or on reservations of New Mexico Indian nations, tribes, or pueblos, provided the patient’s residence is wholly within the state’s exterior boundaries.

The bill reprints Schedule I of the Controlled Substances Act, which includes the existing exemption for peyote in bona fide religious ceremonies. The bill only applies to mushrooms, of course, although this signals awareness and sensitivity to Native American Church concerns in the expansion of plant medicines.

Propagation: Rules were adopted in the summer of 2026. The first producers have been approved, and other applications are in the review process. Psilocybin-containing mushrooms outside of the species cubensis are allowed. The number of producers is not limited, although realistically, the anticipated quantity of psilocybin mushrooms needed is unlikely to support businesses unless they also grow other types of culinary or medicinal mushrooms.

Testing will include five compounds for potency: psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin.

It also includes contaminant testing:

  • Microbial contamination, with E. coli and Salmonella named as examples.
  • Heavy metals, for example lead, cadmium, arsenic, and mercury.

When will services start? The original target of service delivery by the end of 2027 was moved up by a full year. Now, as we approach the end of 2026, there has been impressive progress but a number of pieces of the system still need work. Early 2027 looks more likely for the first patients, with the full program to be rolled out during 2027.

How many people will be served? We will find out. Factors include interest and demand, approval of sites and providers, service delivery capacity, and costs which are still to be determined.

Link: https://www.nmhealth.org/publication/view/guide/9603